Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Asthma, Bronchospasm, Shortness of Breath
Interventions: Virtual Teach to Goal, Brief Intervention; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 5 Years to 10 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: BNT112, Cemiplimab; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Tucson, Arizona • Miami, Florida • Pittsburgh, Pennsylvania + 2 more

Conditions: Leukemia
Interventions: Interview & Questionnaires, Rating Questionnaire, MDASI-CML Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Haemophilia A, Haemophilia A With Inhibitors
Interventions: NNC0365-3769 (Mim8); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 34
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 28 more

Conditions: Diabetes Mellitus, Overweight, Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Escondido, California • Lomita, California + 12 more

Conditions: Autism Spectrum Disorder
Interventions: Autism Pupil Screen (APS) Detect PLR Assessment #1, Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT/R-F), Social Responsiveness Scale, Second Edition (SRS-2), Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), Mullen Scales of Early Learning (MSEL), Adaptive Behavior Assessment System, Third Edition (ABAS-3), Autism Pupil Screen (APS) Detect PLR Assessment #2, Autism Pupil Screen (APS) Detect Assessment #3, Well-child check; Device · Other · Diagnostic Test + 1 more
Lead sponsor: Schweitzer Engineering Laboratories; Industry
Eligibility: 24 Months to 60 Months
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Lewiston, Idaho • Moscow, Idaho • Pullman, Washington

Conditions: Acute Lymphoblastic Leukemia
Interventions: ADCT-402; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: La Jolla, California • New Haven, Connecticut • Atlanta, Georgia + 7 more

Conditions: Metastatic Cancer
Interventions: in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine, Mesna; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Ensifentrine, Placebo, Standard of Care (SOC); Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Hialeah Gardens, Florida • Loxahatchee Groves, Florida • Valparaiso, Indiana + 4 more

Conditions: Wounds, Gunshot
Interventions: Critical Time Intervention, Treatment as Usual, Motivational Interviewing, Multi-Agency Attention; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions: Azeliragon, Stereotactic radiosurgery, Corticosteroid; Drug · Radiation
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Postpartum Depression
Interventions: SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more

Conditions: Pulmonary Arterial Hypertension
Interventions: i.v. selexipag, oral selexipag (Uptravi); Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: La Jolla, California • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: PTM-101; Drug
Lead sponsor: PanTher Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Newport Beach, California • Miami, Florida • Detroit, Michigan + 4 more

Conditions: Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions: PF-07921585, Sasanlimab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more

Conditions: Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Interventions: TAK-007, Chemotherapy Agents; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Brain Tumor
Interventions: [18F]FLT, [18F]Fluciclovine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Norovirus Acute Gastroenteritis
Interventions: mRNA-1403, mRNA-1405, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more

Conditions: NON-ALCOHOLIC STEATOHEPATITIS
Interventions: DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Coronado, California • Montclair, California • Panorama City, California + 12 more

Conditions: Laryngeal Squamous Cell Carcinoma
Interventions: Cisplatin, Epinephrine injection, Laryngeal Biopsy, Endoscopic Surgery; Drug · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more

Conditions: Impulse Control Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Overweight, Diabetes Mellitus Type 2 in Obese
Interventions: P11187, Placebo; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anemia
Interventions: Sotatercept, Placebo; Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 24
States / cities: Azusa, California • Glendale, California • La Mesa, California + 16 more

Search by objective public record fields.

Virtual Teach-to-Goal Education vs. Brief Education for Children

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Symptom Burden in Chronic Myeloid Leukemia (CML)

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in Routine Healthcare

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)

Helping Individuals With Firearm Injuries

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.